acute

Researchers from Singapore have identified a potential dietary supplement that may improve recovery following acute kidney injury (AKI). The finding, published in the Journal of Lipid Research, comes from a long-running research programme…

Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4Dose Level 4 exposure correlates with initial activity…

Pune, India, July 18, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners new research study on "Medical Beds Market Size Report, Share, Revenue & Trends Forecast to 2027 - Global Analysis by Usage, Type, Application, and End…

Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years after infusionSingle-cell analysis of…

Opioid pain-relieving medicines are not more effective than a placebo in relieving acute back and neck pain and may even cause harm, according to a world-first trial led by the University of Sydney. The researchers say this is proof that…

Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseline compared to placebo at 2 hours (p=0.0112) Met key secondary endpoint with…

Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen…

NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of…

DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE)…

New York. USA, June 13, 2023 (GLOBE NEWSWIRE) -- Acute Lung Injury Market is Expected to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies to Look Out - AstraZeneca, Asklepion, Reven, GEn1E, Organicell Regenerative…